– Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure – Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid…